WO2005065102A2 - Improved method and apparatus for measuring cell-by-cell hemoglobin - Google Patents
Improved method and apparatus for measuring cell-by-cell hemoglobin Download PDFInfo
- Publication number
- WO2005065102A2 WO2005065102A2 PCT/US2004/040130 US2004040130W WO2005065102A2 WO 2005065102 A2 WO2005065102 A2 WO 2005065102A2 US 2004040130 W US2004040130 W US 2004040130W WO 2005065102 A2 WO2005065102 A2 WO 2005065102A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- hemoglobin
- cells
- red
- radiation
- Prior art date
Links
- 108010054147 Hemoglobins Proteins 0.000 title claims abstract description 85
- 102000001554 Hemoglobins Human genes 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 25
- 210000004027 cell Anatomy 0.000 claims abstract description 157
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 30
- 230000003287 optical effect Effects 0.000 claims abstract description 30
- 230000005855 radiation Effects 0.000 claims abstract description 27
- 210000004369 blood Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 41
- 238000002310 reflectometry Methods 0.000 claims description 15
- 239000013307 optical fiber Substances 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 8
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 8
- 239000007789 gas Substances 0.000 claims description 6
- 230000001678 irradiating effect Effects 0.000 claims description 6
- 238000003491 array Methods 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 239000003599 detergent Substances 0.000 claims description 3
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 claims description 3
- 238000009826 distribution Methods 0.000 abstract description 10
- 239000000523 sample Substances 0.000 description 38
- 238000005259 measurement Methods 0.000 description 14
- 230000003595 spectral effect Effects 0.000 description 7
- 238000006213 oxygenation reaction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010064719 Oxyhemoglobins Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 2
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 230000000215 hyperchromic effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100001020 decreased hemoglobin concentration Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000009652 hydrodynamic focusing Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/726—Devices
-
- G01N2015/012—
Definitions
- This invention relates to improvements in methods and apparatus for measuring the hemoglobin content of individual red blood cells of a whole blood sample. More particularly, this invention relates to a method for measuring a red blood cell's hemoglobin content on the basis of its reflectivity to radiation at a particular wavelength or wavelengths.
- red blood cell count i.e., the red blood cell count, or RBC
- PCV the volume percentage of red cells in a whole blood sample
- Hgb the amount of hemoglobin per unit volume of whole blood
- MCV the average size of the red cells
- RDW Red Cell Distribution Width, or RDW
- MCH the average amount of hemoglobin in each blood cell
- MCHC the average concentration of hemoglobin within the red blood cells as a whole
- red cell parameters are also useful in fully assessing a blood sample to provide an early diagnosis and/or treatment of disease.
- Red cells of the same blood sample can substantially differ in their hemoglobin content. When a smear of red cells is viewed under a microscope, the amount of hemoglobin in each red cell correlates well with its color; the brighter red in color, the more hemoglobin within the cell. Having knowledge of the statistical distribution of the individual cell hemoglobin concentrations within a population adds significant information concerning the health of a patient.
- Red cells with decreased hemoglobin concentration are called hypochromic, while red cells with increased hemoglobin concentration are termed hyperchromic.
- Populations with an increased distribution of hemoglobin concentrations i.e., a wide disparity of concentrations) are classified as polychromatophilic.
- Hyperchromic red cells have altered flow properties and have been suggested as the cellular cause of diseases such as sickle cell anemia.
- Such measurements are commonly effected by flow cytometric techniques in which the forward light-scattering (FLS) properties, DC voIume(V) and/or RF conductivity (C) of individual cells are determined as each cell passes, one-by-one, through a tiny sensing aperture formed in a cytometric flow cell.
- FLS forward light-scattering
- C RF conductivity
- red cells i.e., red cells that have been treated to render them substantially spherical in shape
- sphered red cells are illuminated by a laser beam as they pass single file through the sensing aperture of an optical (transparent) flow cell.
- the level of forwardly scattered light from each cell is monitored within two angular regions, and an appropriate algorithm is used to determine each cell's hemoglobin concentration and volume on the basis the two light scatter measurements made.
- volume is measured by the standard Coulter Principle according to which a change in a low frequency or DC current (caused to pass through the sensing aperture of a flow cell simultaneously with the passage of cells) indicates the size (volume ) of the cell passing through the aperture.
- the patentee relies on the supposition that the index of refraction of individual cells, which determines the forward light scattering characteristics, is directly related to the hemoglobin concentration of the cells. This supposition, however, is not necessarily true. It is known that at least about 95% of the interior of a red blood cell is a mixture of hemoglobin molecules and water molecules, and the relative proportions of these two molecules is variable; thus the index or refraction, is variable.
- the remaining 5% of the interior volume of the red blood cell is composed mainly of salts which have a large effect on the index or refraction, especially, when the hemoglobin concentration is very low.
- Tycko teaches that by determining the index of refraction by measuring the forward light-scatter intensity within a predetermined angular range, and using the volume of the cell as determined by the DC current measurement through the sensing aperture, the hemoglobin concentration of the cell can be computed.
- the hemoglobin concentration is determined by a non-optical technique in which changes in DC and RF currents passing through the sensing aperture simultaneously with the passage of the individual red cells are monitored.
- the flow cell aperture must be relatively small in cross-section (preferably about 50 x 50 microns) in order to achieve a readily detectable change in the RF current. This requirement impacts the overall reliability of the device, since the small aperture can be subject to frequent blockage caused by clumps of cells or debris in the system.
- Another disadvantage of this technique is the requirement that the conductivity of the diluting fluid required in making the measurement be well controlled to achieve reproducible results.
- an object of the present invention is to provide a simpler and more reliable method for determining the hemoglobin concentration of individual red blood cells in a whole blood sample.
- this invention it has been discovered that the reflectivity of red cells to radiation at certain wavelengths accurately correlates with the amount of hemoglobin within the cell.
- the present invention determines the cell-by-cell hemoglobin by monitoring only the light reflected (i.e., back- scattered) from irradiated individual red cells at an appropriate wavelength, i.e., a wavelength at which the hemoglobin content of the cells has a relatively strong effect on the intensity of the reflected light.
- the red cells are sphered prior to analysis and subjected to an oxygen-enriched sphering solution, preferably one containing carbon monoxide, in order to effect substantially uniform and stable oxygenation of the hemoglobin within the cells, whereby the level of reflected light from the red cells is not dependent on the orientation of the red cell in the measurement zone or on the state of oxygenation of the cell at the time the sample is obtained.
- an oxygen-enriched sphering solution preferably one containing carbon monoxide
- a method for measuring the hemoglobin content of individual red cells in a whole blood sample comprises the steps of: (a) diluting a whole blood sample in a buffer solution; (b) passing the red cells of the diluted sample, one-at-a-time, through an optical interrogation zone; (c) irradiating each red cell as it passes through the optical interrogation zone with a beam of radiation of predetermined wavelength; (d) detecting the level of radiation reflected from each of the irradiated cells within a predetermined angular range; and (e) determining the hemoglobin concentration of each irradiated cell on the basis of the level of reflected radiation detected.
- the buffer solution contains a chemical reagent adapted to render the red cells substantially spherical in shape, and an oxygen-containing gas, preferably carbon monoxide, adapted to diffuse into a red cell and uniformly oxygenate the hemoglobin contents thereof to form a stable compound, e.g., carboxyhemoglobin.
- an improved apparatus for determining the hemoglobin content of individual red cells is provided.
- such apparatus comprises (a) an optical flow cell defining an optical interrogation zone through which red cells can be made to pass, one cell at a time; (b) an optical system including a laser for producing a beam of radiation of predetermined wavelength, such beam being acting to irradiated each red cell as it passes through the interrogation zone of the optical flow cell; (c) a reflectance detector for detecting the level of radiation reflected from each of the irradiated cells within a predetermined angular range; and (d) computational means for determining the hemoglobin concentration of each irradiated cell on the basis of the level of reflected radiation detected.
- FIG. 1 is a graph illustrating the spectral reflectance characteristics of deoxygenated and carboxygenated whole blood
- FIG. 2 is a graph illustrating the mean reflectance of different whole blood samples versus the Mean Cell Hemoglobin (MCH) of each sample
- FIGS. 3 and 4 are cell hemoglobin distributions for normal and abnormally low hemoglobin values, respectively
- FIG. 5 is a schematic illustration of an electro-optical system embodying the present invention
- FIGS. 6A-6C illustrate various details of a preferred reflectance detector.
- red blood cells In the normal circulation of whole blood through the human body, the constituent blood cells flow in single file through the alveolar capillaries of the lungs. The number of red blood cells (erythrocytes) predominate all other cells by a factor of about 1000: 1. In a sample of whole blood, red blood cells exist typically in numbers of about 5 million cells per cubic microliter, although this number varies greatly due to various disease conditions. Within the membrane of each red cell, about 95% of the volume is occupied by water and hemoglobin molecules.
- the oxygen present in the alveolar capillaries diffuses through the cell membrane and acts to convert virtually all of the hemoglobin within the red cells to a relatively unstable molecular complex known as oxyhemoglobin.
- the red blood cells become bright red in color.
- the association of the oxygen and hemoglobin molecules within the red cells is relatively "loose” or unstable, the oxygen molecules gradually disassociate from the hemoglobin molecules. This disassociation occurs as the red cells course through the body, as in the normal circulation of blood. Eventually, the oxygen molecules diffuse out of the red cells and back to the tissues for oxidative purposes. As the oxyhemoglobin reduces to hemoglobin, the red cells become dark red in color.
- the spectral characteristics of the red cells depends on the instantaneous state of oxygenation.
- the respective spectral reflectances of oxygenated and deoxygenated whole blood are shown in FIG.1.
- the reflectivity of both forms of blood is relatively low in the spectral region below about 600 nm.
- the rate of increase in reflectivity of oxygenated blood outpaces that of deoxygenated blood.
- the difference in reflectivity of oxygenated and deoxygenated blood is substantial.
- red cell reflectance measurements are made in accordance with the invention.
- other wavelengths preferably longer than 635 nm, can be used for this reflectance measurement, but 635 nm is a preferred wavelength due to the size and availability of solid-state lasers (e.g., gallium-arsenide diode lasers) that emit at this wavelength.
- solid-state lasers e.g., gallium-arsenide diode lasers
- the amount of hemoglobin in the individual red cells of a blood sample on the basis of spectral reflectivity measurements, as is the case of the present invention, it is desirable to have all of the hemoglobin in the sample at the same level of oxygenation, preferably, totally saturated. While one may achieve oxygen-saturated hemoglobin by subjecting the sample to an oxygen atmosphere or solution, the resulting oxyhemoglobin is, as noted above, relatively unstable and short-lived.
- a preferred approach to stabilizing the hemoglobin in a red blood cell sample is to subject the sample to a carbon monoxide-saturated diluting solution, preferably the same solution used to "sphere" the red cells for analysis.
- red cells refers to the common practice of treating the cells with reagents (e.g., the detergent, n- dodecyl-n,n-dimethyl-3-ammonio-1-propane sulfonate, or DDAPS) or with other substances known to those skilled in the art that act to convert the biconcave disc-shape of a normal red cell to that of a sphere, whereby the measurement of its properties as it passes through the sensing zone of a flow cell is not altered by its geometric orientation in the sensing zone.
- reagents e.g., the detergent, n- dodecyl-n,n-dimethyl-3-ammonio-1-propane sulfonate, or DDAPS
- red cells are subjected to a carbon monoxide-enriched atmosphere, the oxygen molecules of the gas readily bind with the hemoglobin molecules within the red cells (since carbon monoxide has an affinity for hemoglobin about 200 times greater than oxygen) to form carboxyhemoglobin
- the latter is a highly stable complex having spectral characteristics, including reflectivity, that are virtually identical to those of oxyhemoglobin.
- converting all the hemoglobin in a blood sample to carboxyhemoglobin is easily accomplished by having a high concentration of carbon monoxide in the solution commonly used to both dilute and sphere the red blood cells in a blood sample.
- a series of experiments were conducted on forty different blood samples. Each of these blood samples was analyzed on a Beckman Coulter Model LH750 Hematology Analyzer to determine the mean cell hemoglobin (MCH) value of each sample.
- the MCH is the amount, or mass, of hemoglobin present in an average RBC.
- the MCH parameter is reported in terms of the mean weight of hemoglobin per cell, in picograms (pg).
- the MCH is commonly determined by lysing a predetermined volume of a diluted blood sample in order to disperse the red cell hemoglobin into the surrounding diluent and serum, measuring the optical transmission of the lysed sample at a predetermined wavelength, thereby determining the total amount of hemoglobin in that volume of blood, i.e., the [Hgb] parameter, and dividing that total hemoglobin by the number of red blood cells present per unit volume of sample. The result is obviously an average value for each cell.
- the hemoglobin in each red cell of a blood sample it is possible to report, e.g., in the form of a histogram, the statistical distribution of the cell hemoglobin (CH) in the sample.
- CH cell hemoglobin
- FIG. 3 the distribution of cell hemoglobin in a normal sample is shown as being generally symmetrical in shape, with a majority of cells having cell hemoglobin values of between 23 and 39 picograms.
- FIG. 4 where an abnormal cell hemoglobin distribution is shown, a large number (about 35%) of cells have a cell hemoglobin in the range of 11 to 22 picograms. Had this blood sample been examined microscopically, a large percentage of the cells would have been reported as hypochromic.
- FIG. 5 schematically illustrates a preferred flow cytometric apparatus 10 embodying the invention.
- apparatus 10 is adapted to determine the cell-by-cell hemoglobin concentration (HGC) of red blood cells on the basis of the optical reflection measurements discussed above.
- the preferred apparatus of the invention comprises an optical flow cell 12 of the general type disclosed, for example, in the commonly assigned U.S. Patent No. 6,228,652, issued to C. Rodriguez et al.
- Flow cell 12 is typically fabricated from quartz, a material that is optically-transparent to a radiation used to irradiate cells passing through the flow cell for the purpose of analyzing the optical characteristics of such cells.
- Flow cell 12 defines an hour-glass-shaped central opening 14 comprising a pair of opposing cup- shaped chambers, 16, 18, connected by a tiny cell-interrogation zone Z, sometimes referred to as the "sensing aperture.”
- Chamber 16 is adapted to receive a diluted whole blood sample from a sample supply system 20.
- a sheath liquid 22 comprises a hydrodynamic focusing system that serves, in a well known manner, to train a thin stream of sample cells C through the cell-interrogation zone Z so that the red cells of interest are advanced, substantially one-at-a-time, through the central region of zone Z. Upon passing through zone Z, the diluted sample is discharged through flow cell chamber 18 to waste. 23.
- the cell- interrogation zone Z has a square transverse cross-section, measuring about 100 by 100 microns, and an axial length of at least about 75 microns.
- the cross-sectional area of zone Z is substantially larger than that required by those cytometric flow cells used to monitor the RF conductivity (C) of cells passing through it.
- C RF conductivity
- the construction of the flow cell used in the apparatus of the invention is simplified vis-a-vis such prior art apparatus, and the flow cell yield is significantly greater than those flow cells with the smaller cross-sections.
- each cell C While passing through the central region of zone Z, each cell C is irradiated by a radiation beam B provided by a continuous-wave laser 24 or the like.
- laser 24 comprises a solid-state laser, e.g. a gallium arsenide diode laser, having an emission line at 635 nanometers. As noted below, this wavelength is chosen because of the spectral reflectance characteristics of hemoglobin.
- apparatus 10 further comprises a reflectance detector 30 that is positioned to detect reflected radiation from each of the irradiated cells while it is irradiated within the cell- interrogation zone Z.
- Reflectance detector 30 comprises a conventional photodetector 32, most preferably a photomultiplier tube (PMT) or other high- gain optical detector that is sensitive to the cell-irradiating radiation, and an optical coupler 33 for concentrating reflected radiation onto the photosensitive surface of the photodetector.
- photodetector 32 is optically coupled to the cell-reflected radiation by a bundle of optical fibers 34.
- the respective input ends 36 of the optical fibers 34A are supported by an optical fiber holder 38 having a central opening 39 through which beam B passes as it propagates between the laser source 24 and the cell interrogation zone Z.
- the electrical output of photodetector 32 * is connected to a signal processor 40 having a central processing unit 42 that serves to compare the digitized signal level (from analog-to-digital converter 44) with a stored signal (embedded in PROM 46) representing the relationship between the cell reflectance and its hemoglobin concentration. Having determined the cell-by-cell hemoglobin of the sample, a report 45 is provided, as discussed below.
- the optical coupler 33 is of the type disclosed in the commonly assigned U. S. Patent Application No. 10/227,010, filed on August 23, 2002 in the name of D. L. Kramer.
- Such a device comprises the above-mentioned optical fiber holder 38 which serves to support the light-collecting end portions 36 of each optical fiber 34A so that its respective central axis A is parallel to the axis of the irradiating beam B.
- Holder 38 comprises a cylindrical sleeve 50, about 12.5 mm. in diameter and 20 mm. in length. One end of the sleeve is closed by a plate 52 in which a series of holes 53 are drilled, each hole acting to support the light-collecting end portion of a single optical fiber.
- Each optical fiber has a diameter of about 500 microns.
- Particularly preferred optical fibers are the SI Bare Fiber, sold by Boston Optical Fiber.
- the holes in plate 52 serve to support the light-collecting ends of the optical fibers in three circular arrays, each array being concentrically arranged about the central axis A of the cylindrical sleeve 50 (which coincides with the axis of beam B when the reflectance detector is in use), and each array being at a different radial distance from the beam axis.
- the light-collecting fiber ends are supported in a common plane, and such plane is spaced from the cell-interrogation zone such that the reflected radiation from the cells is collected within an angular range x of between about 4 degrees and about 10 degrees, measured with respect to the beam axis.
- the individual fibers need not be arranged in circular arrays, but these arrays serve as a convenience in fabrication.
- angles of light collected by the optical fibers can be from about 0.5 degrees to about 25 degrees but, as indicated, the preferred angular range is from about 4 degrees to about 10 degrees. Wider angles of light be utilized, but suffer from reduced intensity. Angle less than 4 degrees are effected by stray light and retro reflection from optical surfaces thereby limiting usefulness.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006545694A JP2007514955A (en) | 2003-12-19 | 2004-12-01 | Improved method and apparatus for measuring hemoglobin per cell |
EP04812604A EP1695077A4 (en) | 2003-12-19 | 2004-12-01 | Improved method and apparatus for measuring cell-by-cell hemoglobin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/741,458 US7095492B2 (en) | 2003-12-19 | 2003-12-19 | Method and apparatus for measuring cell-by-cell hemoglobin |
US10/741,458 | 2003-12-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005065102A2 true WO2005065102A2 (en) | 2005-07-21 |
WO2005065102A3 WO2005065102A3 (en) | 2005-09-01 |
Family
ID=34678154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/040130 WO2005065102A2 (en) | 2003-12-19 | 2004-12-01 | Improved method and apparatus for measuring cell-by-cell hemoglobin |
Country Status (4)
Country | Link |
---|---|
US (1) | US7095492B2 (en) |
EP (1) | EP1695077A4 (en) |
JP (1) | JP2007514955A (en) |
WO (1) | WO2005065102A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7541190B2 (en) * | 2005-02-07 | 2009-06-02 | Beckman Coulter, Inc. | Method of measurement of cellular hemoglobin |
JP4822562B2 (en) * | 2006-01-20 | 2011-11-24 | ベックマン コールター, インコーポレイテッド | Low hemoglobin concentration cell percentage and method of use in detecting iron deficiency |
ES2796655T3 (en) | 2008-11-14 | 2020-11-27 | Beckman Coulter Inc | Monolithic Optical Flow Cells and Manufacturing Method |
FR2956207B1 (en) * | 2010-02-10 | 2012-05-04 | Horiba Abx Sas | DEVICE AND METHOD FOR MULTIPARAMETRIC MEASUREMENTS OF MICROPARTICLES IN A FLUID |
US8339586B2 (en) | 2011-04-15 | 2012-12-25 | Constitution Medical, Inc. | Measuring volume and constituents of cells |
WO2016164244A1 (en) * | 2015-04-08 | 2016-10-13 | Indiana University Research And Technology Corporation | Flow assembly for cells |
ES2837438T3 (en) * | 2017-09-29 | 2021-06-30 | Siemens Healthcare Gmbh | Specific detection of malaria with digital light microscopy |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4735504A (en) | 1983-10-31 | 1988-04-05 | Technicon Instruments Corporation | Method and apparatus for determining the volume & index of refraction of particles |
US4711852A (en) | 1984-11-05 | 1987-12-08 | Akzo N.V. | Control for blood gas analyzers and hemoglobin analysis |
US4702598A (en) * | 1985-02-25 | 1987-10-27 | Research Corporation | Flow cytometer |
JP2815435B2 (en) * | 1989-12-22 | 1998-10-27 | 株式会社日立製作所 | Particle analyzer and blood cell counter |
JPH0616774B2 (en) * | 1990-11-07 | 1994-03-09 | テルモ株式会社 | Oxygen saturation measuring device |
US5194909A (en) * | 1990-12-04 | 1993-03-16 | Tycko Daniel H | Apparatus and method for measuring volume and hemoglobin concentration of red blood cells |
US5282466A (en) * | 1991-10-03 | 1994-02-01 | Medtronic, Inc. | System for disabling oximeter in presence of ambient light |
DE69432410T2 (en) * | 1993-05-14 | 2004-03-04 | Coulter International Corp., Miami | RETICULOYCYTE DETERMINATION METHOD AND DEVICE USING LIGHT SCATTERING TECHNIQUES |
JPH08128944A (en) * | 1994-11-01 | 1996-05-21 | Nippon Koden Corp | Particle classifying equipment |
US6984526B2 (en) * | 1995-02-08 | 2006-01-10 | University Of South Florida | Spectrophotometric method for determining the viability of a sample containing platelets |
US6393310B1 (en) * | 1998-09-09 | 2002-05-21 | J. Todd Kuenstner | Methods and systems for clinical analyte determination by visible and infrared spectroscopy |
US6228652B1 (en) * | 1999-02-16 | 2001-05-08 | Coulter International Corp. | Method and apparatus for analyzing cells in a whole blood sample |
AU775260B2 (en) * | 1999-03-31 | 2004-07-29 | Bayer Corporation | Single channel, single dilution detection method |
DE19933275A1 (en) * | 1999-07-14 | 2001-01-18 | Fresenius Ag | Use of hemoglobin derivatives to determine the plasma and / or blood volume |
US6784981B1 (en) * | 2000-06-02 | 2004-08-31 | Idexx Laboratories, Inc. | Flow cytometry-based hematology system |
JP4659252B2 (en) * | 2001-03-29 | 2011-03-30 | シスメックス株式会社 | Flow cytometer |
US6743634B2 (en) | 2002-08-23 | 2004-06-01 | Coulter International Corp. | Method and apparatus for differentiating blood cells using back-scatter |
-
2003
- 2003-12-19 US US10/741,458 patent/US7095492B2/en not_active Expired - Lifetime
-
2004
- 2004-12-01 WO PCT/US2004/040130 patent/WO2005065102A2/en not_active Application Discontinuation
- 2004-12-01 JP JP2006545694A patent/JP2007514955A/en active Pending
- 2004-12-01 EP EP04812604A patent/EP1695077A4/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of EP1695077A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1695077A4 (en) | 2008-03-05 |
JP2007514955A (en) | 2007-06-07 |
US7095492B2 (en) | 2006-08-22 |
EP1695077A2 (en) | 2006-08-30 |
WO2005065102A3 (en) | 2005-09-01 |
US20050134833A1 (en) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3707620B2 (en) | Reticulocyte analysis method and apparatus using light scattering technology | |
US5194909A (en) | Apparatus and method for measuring volume and hemoglobin concentration of red blood cells | |
CA2410894C (en) | Flow cytometry-based hematology system | |
KR970007077B1 (en) | Multi-part diefferential analyzing apparatus using light scatter techniques | |
JP4184258B2 (en) | Optical red blood cell and white blood cell discrimination | |
JP4468590B2 (en) | Cell analysis method and apparatus for whole blood sample | |
CA2468513C (en) | Analysis method and system therefor | |
CA1144280A (en) | Automated method for cell volume determination | |
US5851835A (en) | Multiparameter hematology apparatus and method | |
EP2534467B1 (en) | Device and method for multiparameter measurements of microparticles in a fluid | |
JPH10504398A (en) | A rapid and simultaneous method for analyzing nucleated red blood cells | |
EP0941464A2 (en) | Apparatus and method for determination of individual red blood cell shape | |
KR20150103005A (en) | Immature platelet enumeration systems and methods | |
EP2021764B1 (en) | Method to detect states of anemia present in a blood sample | |
US7095492B2 (en) | Method and apparatus for measuring cell-by-cell hemoglobin | |
US6788394B1 (en) | Spectrophotometric system and method for the identification and characterization of a particle in a bodily fluid | |
WO2002004947A2 (en) | Spectrophotometric system and method for the identification and characterization of a particle in a bodily fluid | |
Gray et al. | A new method for cell volume measurement based on volume exclusion of a fluorescent dye | |
AU2001263405B2 (en) | Flow cytometry-based hematology system | |
Murakawa et al. | Application of diffractometry and a linear image sensor to measurement of erythrocyte deformability | |
WO2023242387A1 (en) | Automated fluorescence-based quantification of pocked red cells | |
CN105334191A (en) | Hemoglobin concentration and volume correction method and apparatus for individual erythrocyte | |
AU2001263405A1 (en) | Flow cytometry-based hematology system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004812604 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006545694 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004812604 Country of ref document: EP |